This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Ken Mulvany Appointed Chairman Of The Cure Parkinson's Trust

LONDON, March 18, 2013 /PRNewswire/ --

The Cure Parkinson's Trust, a charity founded by four people with Parkinson's disease, which is dedicated to finding, facilitating and funding work towards a cure, today welcomes Kenneth Mulvany to the charity as Chairman. 

Ken Mulvany is an entrepreneur and healthcare industry veteran and brings more than 15 years of business leadership and experience to The Cure Parkinson's Trust. Ken was previously CEO of Proximagen, a UK-based biotech company committed to delivering novel drugs and innovative new treatments for Central Nervous System (CNS) disorders. Proximagen was acquired in August 2012 by Upsher-Smith Laboratories, Inc. in the US where this pipeline of CNS programmes continues to be advanced.  

Sir Richard Nichols, former Lord Mayor of London, and co-founder of the charity, has stepped down as Chairman after eight successful and supportive years during which the Charity has grown significantly and firmly cemented its vision of providing support towards finding a cure for Parkinson's. 

Tom Isaacs, Co-founder and President of The Cure Parkinson's Trust, said: "We welcome Ken Mulvany to the Charity and look forward to working with him as he puts a new perspective on problem solving and bringing fresh ideas to moving potential new therapies forward to halt, and reverse Parkinson's. Due to his entrepreneurial vision and industry background, we believe Ken is going to be a strong follow-on Chairman to Sir Richard. He will guide us in fostering new and effective relationships with industry that can help us fulfil our vision to fund innovative research and find a cure for Parkinson's.  On behalf of the charity I want to thank Sir Richard Nichols for his inspirational and dedicated chairmanship."

The newly appointed Chairman of The Cure Parkinson's Trust, Ken Mulvany, said: "I have known Tom and the team at The Cure Parkinson's Trust for many years now and thoroughly admire the work the team plus all of the fantastic supporters have been doing to fulfil the charity's vision. Their success has enabled the charity to fund innovative research and inspirational scientists whose work is starting to make a difference as trials into new treatments get underway. I very much hope I can bring connections to the pharmaceutical industry and additional support that will help to advance potential cures for Parkinson's."

Sir Richard Nichols, former Chairman of The Cure Parkinson's Trust, added: "Since we founded The Cure Parkinson's Trust in 2005, we have seen so much change in the field of Parkinson's research. It is very encouraging to know that we are on the cusp of major breakthroughs in Parkinson's, and new areas are being investigated fruitfully. It has been a privilege to lead this dynamic organisation since its inception, and I am delighted that Ken has the vision and determination to enable the Trust to reach its goal of finding cures for Parkinson's."

Notes for Editors:

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs